The fusion of plasma membrane with the internal vesicle fusion leads to the secretion of nanovescicles called exosomes into the extracellular environment. The exosomes are released in easily accessible body fluids such as urine and blood and hence acts as a precious source of biomedical tool. As cancer is a booming research area, exosomes may act as a very useful biomarkers for the diagnosis and prognosis of malignant tumor. The application of exosome as a potential biomarker for the various neurodegenerative disorders is also under investigation. All this is expected to create a new market where the industry payers can focus on new product developments.
Diagnostic Exosome Biomarkers Market: Drivers and Restraints
Exosomes are the biomimetic nanovectors for a variety of nucleic acid, chemicals and proteins. Exosome-encapsulated curcumin, delivered by the intranasal route is efficient in preventing brain inflammation, and specific gene silencing miRNAs enclosed in targeted exosomes and delivered systemically have shown promising therapeutic effects. Exosomes biomarkers fix in the ideal theranostic approach as they can act as biomarkers or vectors of therapeutic molecules. The theranostic approach is very prominent in personalized medicine where the individual is monitored and diagnosed for a particular mode of treatment. The exosome biomarkers also help in providing targeted drug delivery system thereby providing a very potential market.
Diagnostic Exosome Biomarkers Market: Overview
The extracellular vesicles called exosomes are sized around 100 nm in diameter, which are released from many different cell types. Exosomes are produced by different mechanism and hence differ from other class of extracellular vesicles and microvesicles that are different in size too. Exosomes contains a range of biomolecules including membrane-bound and soluble proteins, microRNA, lipids and noncoding RNA. Therefore exosomes are a good source of disease biomarkers for early diagnosis and/or prediction of disease progression.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5564
Diagnostic Exosome Biomarkers Market: Region-wise Outlook
In terms of geography, diagnostic exosome biomarkers market has been divided into seven regions including North- America, Eastern Europe, Western Europe, Asia- Pacific excluding Japan, Japan Middle-East & Africa and Latin America. North America is expected to remain the dominating region while Asia Pacific is expected to emerge as a fastest growing region. In 2016, the National Institutes of Health is seeking grant applications for projects investigating the potential of exosomes and extracellular vesicles (EVs), as well as their cargo, as biomarkers for cancer risk assessment, detection, diagnosis, and prognosis. Such research funding and government support is expected to accelerate the growth of the diagnostic exosome biomarkers market.
Diagnostic Exosome Biomarkers Market: Key Market Participants
The diagnostic exosome biomarker market players are expanding their laboratory capacities to fit in to the increasing demand. Exosome Diagnostics moved into its new ISO 13485certified facility, built for the company’s patented liquid-biopsy sample processing and analysis technologies.
Some of the diagnostic exosome biomarkers market participants are 101Bio, AMS Biotechnology Limited, BioRegenerative Sciences, Inc., Cell Guidance Systems LLC, Codiak BioSciences, Evomic Science LLC, ExoCyte Therapeutics Pte Ltd, Exosome Diagnostics, Inc, Exovita biosciences, Immune Therapy Holdings AB, Lonza Group, Norgen Biotek Corp., ReNeuron Group plc and Therapeutic Solutions International, Inc.